GuruFocus
13 Jun 2026, 16:00 UTC · 12h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Search tags
What the story claims
2 claims · each scored for market impact
Incyte announced positive updated clinical data for INCA033989, showing rapid, robust, and sustained clinical and molecular responses in patients with myelofibrosis. — Strong positive clinical trial results for a first-in-class drug typically drive significant upward price movement for biotechnology stocks.
+0.60INCA033989 was found to be well tolerated in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). — Safety and tolerability are critical hurdles for FDA approval; positive results reduce the risk of trial failure.
+0.30Which stocks this story touches
The company announced positive clinical data showing rapid and robust responses for its INCA033989 antibody.
Continue reading
5 related stories
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Business Wire
18h ago
